NASDAQ:MRSN

Mersana Therapeutics Stock Forecast, Price & News

$21.09

+0.33 (+1.59 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$20.06

Now: $21.09▼

$21.28

50-Day Range

$18.12

MA: $23.94▼

$27.59

52-Week Range

$4.12

Now: $21.09▼

$29.09

Volume1.14 million shs

Average Volume1.62 million shs

Market Capitalization$1.44 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.54

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.56 out of 5 stars

Medical Sector

300th out of 1,558 stocks

Pharmaceutical Preparations Industry

159th out of 638 stocks

3.4 Analyst's Opinion

Consensus Rating
Mersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.80, Mersana Therapeutics has a forecasted upside of 31.8% from its current price of $21.09.
Amount of Analyst Coverage
Mersana Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Mersana Therapeutics has received 226 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Mersana Therapeutics has received 198 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Mersana Therapeutics has received 53.30% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote “Outperform” if you believe MRSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Mersana Therapeutics does not currently pay a dividend.
Dividend Growth
Mersana Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mersana Therapeutics insiders have bought 1,246.52% more of their company's stock than they have sold. Specifically, they have bought $6,429,000.00 in company stock and sold $477,453.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Mersana Therapeutics is held by insiders.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Mersana Therapeutics are expected to decrease in the coming year, from ($1.33) to ($1.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mersana Therapeutics is -15.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mersana Therapeutics is -15.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mersana Therapeutics has a P/B Ratio of 12.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MRSN

Previous Symbol

CUSIPN/A

CIK1442836

Webwww.mersana.com

Phone617-498-0020

Employees83

Debt

Debt-to-Equity Ratio0.02

Current Ratio13.05

Quick Ratio13.05

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$42.12 million

Price / Sales34.30

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.64 per share

Price / Book12.86

Profitability

EPS (Most Recent Fiscal Year)($0.65)

Net Income$-28,210,000.00

Net Margins-8,772.91%

Return on Equity-45.16%

Return on Assets-37.53%

Miscellaneous

Outstanding Shares68,500,000

Market Cap$1.44 billion

Next Earnings Date2/26/2021 (Estimated)

OptionableNot Optionable

$21.09

+0.33 (+1.59 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

How has Mersana Therapeutics' stock been impacted by Coronavirus?

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRSN stock has increased by 226.5% and is now trading at $21.09.
View which stocks have been most impacted by COVID-19.

Is Mersana Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mersana Therapeutics stock.
View analyst ratings for Mersana Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Mersana Therapeutics?

Wall Street analysts have given Mersana Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mersana Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, February 26th 2021.
View our earnings forecast for Mersana Therapeutics.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its quarterly earnings data on Monday, November, 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.02. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.43 million. Mersana Therapeutics had a negative net margin of 8,772.91% and a negative return on equity of 45.16%.
View Mersana Therapeutics' earnings history.

What price target have analysts set for MRSN?

6 brokerages have issued 12 month price objectives for Mersana Therapeutics' shares. Their forecasts range from $20.00 to $33.00. On average, they expect Mersana Therapeutics' stock price to reach $27.80 in the next twelve months. This suggests a possible upside of 31.8% from the stock's current price.
View analysts' price targets for Mersana Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Mersana Therapeutics' key competitors?

Some companies that are related to Mersana Therapeutics include Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Eidos Therapeutics (EIDX), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), Maravai LifeSciences (MRVI), Hutchison China MediTech (HCM), Atea Pharmaceuticals (AVIR), Arvinas (ARVN), ChemoCentryx (CCXI), GW Pharmaceuticals (GWPH), Hypera (HYPMY), Apellis Pharmaceuticals (APLS), Reata Pharmaceuticals (RETA) and MorphoSys (MOR).
View all of MRSN's competitors.

What other stocks do shareholders of Mersana Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology Group (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the following people:

Ms. Anna Protopapas, Pres, CEO & Director (Age 57, Pay $833.15k)
Mr. Brian C. DeSchuytner, Sr. VP of Fin. & Product Strategy (Age 43, Pay $456.82k)
Mr. Mikhail Papisov Ph.D., Co-Founder
Mr. Ashish Mandelia, VP, Controller & Principal Accounting Officer (Age 47)
Dr. Timothy B. Lowinger, Chief Science & Technology Officer (Age 57)
Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications
Ms. Radha Iyengar, VP of Legal Operations
Dr. Michael Kaufman, Chief Manufacturing Officer (Age 63)
Mr. Chuck Miller, Sr. VP of Regulatory Affairs
Mr. Marc Damelin, Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $21.09.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $1.44 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 83 workers across the globe.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is www.mersana.com.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here